Venice’s $65M Raise Makes VVV Holders Reconsider Growth
Venice AI closes a $65 million Series A led by Dragonfly at a $1 billion valuation, funding growth with equity. The m...
Which Index Fund Is Best After Ira Rollover
After an IRA rollover, selecting the right index fund matters for long-term growth and risk management. Compare options and choose confidently.
26,327 articles
Bitcoin’s Early July Bounce Stumbles on Thin Liquidity
Bitcoin climbs in early July trading, but analysts caution that liquidity gaps and a large underwater supply could ca...
This Keep Buying Meta Stock: AI Edge and Vertical Power
Meta Platforms is signaling a durable AI-led growth path through vertical control of compute, power, silicon, and ads...
Micron’s Right Could Lift Memory ETFs Through 2027
Micron’s latest earnings hints at a longer memory cycle, potentially lifting these memory ETFs through 2027. Here’s h...
MSTR Lost Year, Bitcoin Slump Tests Strategy's Bet
MicroStrategy confronts a pivotal test as its Bitcoin treasury faces a brutal market. With BTC below its purchase pri...
Ethereum Locks FOCIL 2026: Foundation Moves ETH to Staking
Ethereum confirms FOCIL will join the Hegota upgrade in 2026 while the Ethereum Foundation redirects a portion of its...
DraftKings Expanding Beyond Traditional Markets: Buy or Not?
DraftKings is diversifying beyond its core betting business. This article examines what that shift could mean for inv...
As Annual Recurring Revenue Accelerates, CrowdStrike Buy?
CrowdStrike’s ARR growth has reaccelerated, but does that make the stock a buy? This guide breaks down ARR health, ma...
XRP Keeps Stalling $1.45: Price Faces Major Hurdle
XRP remains trapped around $1.45, facing a tough resistance zone between $1.76 and $1.80. On-chain data shows a large...
Wall Street Expected Soar: Why SYM Bulls May Fall Short
Symbotic's shiny narrative has investors buzzing, but the biggest gains often hinge on real execution, not just optim...
Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Mastering a Good 2026 Earnings Transcript for Investors
The first quarter of 2026 offers clues about corporate health and future growth. This guide explains how to read a go...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status